{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:36:15Z","timestamp":1775291775687,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Finnish Cancer Society"},{"name":"Oulu University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00432-018-2682-9","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T10:12:21Z","timestamp":1528193541000},"page":"1613-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients"],"prefix":"10.1007","volume":"144","author":[{"given":"Tiina","family":"Moilanen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Jokim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Tenhunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-1640","authenticated-orcid":false,"given":"Jussi P.","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"issue":"8","key":"2682_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cardfail.2014.05.012","volume":"20","author":"KB Baron","year":"2014","unstructured":"Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KHR et al (2014) Trastuzumab-induced cardiomyopathy: Incidence and associated risk factors in an inner-city population. J Card Fail 20(8):555\u2013559. \n                    https:\/\/doi.org\/10.1016\/j.cardfail.2014.05.012","journal-title":"J Card Fail"},{"issue":"2","key":"2682_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S, Im S, Hegg R, Im Y et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"issue":"17","key":"2682_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/jnci\/djs317","volume":"104","author":"EJA Bowles","year":"2012","unstructured":"Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293\u20131305. \n                    https:\/\/doi.org\/10.1093\/jnci\/djs317","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"2682_CR4","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.2001.19.10.2722","volume":"19","author":"HJ Burstein","year":"2001","unstructured":"Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM et al (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19(10):2722\u20132730. \n                    https:\/\/doi.org\/10.1200\/JCO.2001.19.10.2722","journal-title":"J Clin Oncol"},{"issue":"25","key":"2682_CR5","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910\u20133916. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.27.3615","journal-title":"J Clin Oncol"},{"issue":"5","key":"2682_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone SA, Zhao Y, Fan L, Gu Y, Minamisawa S, Liu Y et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8(5):459\u2013465. \n                    https:\/\/doi.org\/10.1038\/nm0502-459","journal-title":"Nat Med"},{"issue":"11","key":"2682_CR7","doi-asserted-by":"publisher","first-page":"e79543","DOI":"10.1371\/journal.pone.0079543","volume":"8","author":"MK ElZarrad","year":"2013","unstructured":"ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS et al (2013) Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLOS One 8(11):e79543. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0079543","journal-title":"PLOS One"},{"key":"2682_CR29","unstructured":"FDA (2017) Trastuzumab prescribing information. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103792s5337lbl.pdf\n                    \n                  . Accessed 5 June 2018"},{"key":"2682_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006915","author":"R Florido","year":"2017","unstructured":"Florido R, Smith KL, Cuomo KK, Russell SD (2017) Cardiotoxicity from human epidermal growth factor receptor-2 (HER2) targeted therapies. J Am Heart Assoc. \n                    https:\/\/doi.org\/10.1161\/JAHA.117.006915","journal-title":"J Am Heart Assoc"},{"issue":"26","key":"2682_CR9","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733\u20132743. \n                    https:\/\/doi.org\/10.1056\/NEJMoa064320","journal-title":"N Engl J Med"},{"issue":"9897","key":"2682_CR10","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","volume":"382","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Gelber RD, Piccart-Gebhart M, de Azambuja E, Procter M, Suter TM et al (2013) 2\u00a0years versus 1\u00a0year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021\u20131028. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61094-6","journal-title":"Lancet"},{"issue":"25","key":"2682_CR11","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand J, Broglio K, Hess KR et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. anderson cancer center experience. J Clin Oncol 24(25):4107\u20134115. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.04.9551","journal-title":"J Clin Oncol"},{"issue":"26","key":"2682_CR12","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","volume":"34","author":"C Guenancia","year":"2016","unstructured":"Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F et al (2016) Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 34(26):3157\u20133165. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.4846","journal-title":"J Clin Oncol"},{"issue":"8","key":"2682_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","volume":"354","author":"H Joensuu","year":"2006","unstructured":"Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8):809\u2013820. \n                    https:\/\/doi.org\/10.1056\/NEJMoa053028","journal-title":"N Engl J Med"},{"key":"2682_CR14","doi-asserted-by":"publisher","unstructured":"Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2\u2013Positive, hormone Receptor\u2013Positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. 27(33):5529\u20135537. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.20.6847","DOI":"10.1200\/JCO.2008.20.6847"},{"issue":"6555","key":"2682_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/378394a0","volume":"378","author":"KF Lee","year":"1995","unstructured":"Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378(6555):394\u2013398. \n                    https:\/\/doi.org\/10.1038\/378394a0","journal-title":"Nature"},{"key":"2682_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006243.pub2","author":"L Moja","year":"2012","unstructured":"Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. \n                    https:\/\/doi.org\/10.1002\/14651858.CD006243.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"2682_CR17","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1111\/bph.13643","volume":"174","author":"BT Nemeth","year":"2017","unstructured":"Nemeth BT, Varga ZV, Wu WJ, Pacher P (2017) Trastuzumab cardiotoxicity: from clinical trials to experimental studies. Br J Pharmacol 174(21):3727\u20133748. \n                    https:\/\/doi.org\/10.1111\/bph.13643","journal-title":"Br J Pharmacol"},{"issue":"16","key":"2682_CR18","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"M Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659\u20131672. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052306","journal-title":"N Engl J Med"},{"issue":"16","key":"2682_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673\u20131684. \n                    https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"issue":"5","key":"2682_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","volume":"21","author":"SC Seferina","year":"2016","unstructured":"Seferina SC, de Boer M, Derksen MW, van dB, van Kampen R,JW, van de Wouw A,J et al (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice: a study of the southeast Netherlands breast cancer consortium. Oncologist 21(5):555\u2013562. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2015-0230","journal-title":"Oncologist"},{"issue":"4785","key":"2682_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235(4785):177\u2013182","journal-title":"Science"},{"issue":"4905","key":"2682_CR22","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707\u2013712","journal-title":"Science"},{"issue":"11","key":"2682_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792. \n                    https:\/\/doi.org\/10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"issue":"8","key":"2682_CR24","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim S, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724\u2013734. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"2682_CR25","doi-asserted-by":"publisher","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. 25(23):3525\u20133533. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.11.0106","DOI":"10.1200\/JCO.2007.11.0106"},{"issue":"19","key":"2682_CR26","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"2682_CR27","doi-asserted-by":"publisher","unstructured":"von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2\u2013Positive advanced breast cancer: A german breast group 26\/breast international group 03\u201305 study. 27(12):1999\u20132006. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.19.6618","DOI":"10.1200\/JCO.2008.19.6618"},{"issue":"2","key":"2682_CR28","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10549-014-3253-7","volume":"149","author":"AF Yu","year":"2015","unstructured":"Yu AF, Yadav NU, Lung BY, Eaton AA, Thaler HT, Hudis CA et al (2015) Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer. Breast Cancer Res Treat 149(2):489\u2013495. \n                    https:\/\/doi.org\/10.1007\/s10549-014-3253-7","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-018-2682-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-018-2682-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T19:10:02Z","timestamp":1559675402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-018-2682-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1007\/s00432-018-2682-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"assertion":[{"value":"20 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest. The study was funded by Oulu University Hospital, University of Oulu, and Finnish Cancer Society. According to national legislation, informed consent is not needed due to retrospective and non-interventional nature of the study. The opinions expressed in this article are the personal views of the author (OT) and may not be understood or quoted as being behalf or reflect the position of the Finnish Medicines Agency or European Medicines Agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}